In contrast, the compound genipin 1-gentiobioside has been identified as a promising novel DPP-IV inhibitor that is effective, low-cost, and non-toxic, and its potential as a lead compound for the management of T2D warrants further investigation. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.